Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707 | EVP & President, TR&DT | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTEGRA LIFESCIENCES HOLDINGS CORP
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 54,530 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 11,180 · Balance 54,530 F1: Grant of restricted stock units ("RSUs") pursuant to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2: All RSUs reported in this row were granted under the Plan and will vest in full on the second anniversary of the grant date, subject to the Reporting Person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") pursuant to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: All RSUs reported in this row were granted under the Plan and will vest in full on the second anniversary of the grant date, subject to the Reporting Person's continued service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2017 Filed Mar 15, 2017 20:13 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 328 | $43.03 | $14,113.84 |
DisclosureSEC source: 0001209191-17-020780 · doc4.xml · nonDerivative · entry 3 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,241 Read SEC document |
| March 14, 2017 Filed Mar 15, 2017 20:13 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | Tax withholdingCommon Stock | 1,230 | $43.03 | $52,926.90 |
DisclosureSEC source: 0001209191-17-020780 · doc4.xml · nonDerivative · entry 2 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,569 Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 20:13 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,062 | $0.00 Strike: $43.68 | $0.00 |
DisclosureSEC source: 0001209191-17-020780 · doc4.xml · derivative · entry 4 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,062 Underlying: Common Stock · 11,062 shares Expires 2025-03-13 F1 · derivative.exercise_date: 25% of the stock options vest every first, second, third and fourth anniversaries of the grant date of 3/13/2017. Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 20:13 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 2,862 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-020780 · doc4.xml · nonDerivative · entry 1 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,799 Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 21:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 3,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-012111 · doc4.xml · nonDerivative · entry 3 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,937 F4 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2017 at 150% target, the first anniversary of the grant date. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 21:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 1,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-012111 · doc4.xml · nonDerivative · entry 2 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,292 F3 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 23, 2015 Performance Stock Award. Accordingly, 33% of the shares will vest on March 23, 2017, the second anniversary of the grant date. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 21:30 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantCommon Stock | 2,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-012111 · doc4.xml · nonDerivative · entry 1 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,690 F1 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 24, 2014 Performance Stock Award. Accordingly, 34% of the shares will vest on March 24, 2017, the third anniversary of the grant date. F2 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date and one additional unit of unvested performance based restricted stock ("PSU") for each PSU owned as of that date, as reflected in the totals listed on this Form 4. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 21:09 UTC | INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,705 | $0.00 Strike: $76.85 | $0.00 |
DisclosureSEC source: 0001209191-16-153325 · doc4.xml · derivative · entry 1 DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,705 Underlying: Common Stock · 8,705 shares Expires 2024-12-01 F1 · derivative.exercise_date: 100% of the shares of stock options will vest on the third anniversary of the grant date of 12/01/2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.